metaPreg - Semaglutide during pregnancy

Semaglutide updated on 01-05-2026

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
2 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Preterm (< 37 weeks)	4.95 [1.80, 13.59]	-	1 study	4,852	30	not evaluable	ROB	9.37 [3.01; .]
Large for gestational age (weight)	5.94 [2.16, 16.36]	-	1 study	4,190	29	not evaluable	ROB	11.36 [3.74; .]
1 non statistically significant endpoints reported in only one study
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Caesarean	-	-	0 study					-
Gestational diabetes	-	-	0 study					-
Preeclampsia	-	-	0 study					-
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Jaundice / Icterus	3.31 [1.11, 9.90]	-	1 study	5,952	29	not evaluable	ROB	6.08 [1.45; .]
Neonatal hypoglycemia	7.89 [1.92, 32.39]	-	1 study	1,451	29	not evaluable	ROB	15.26 [3.25; .]
Neonatal medical care	-	-	0 study					-